RESEARCH INSTITUTES OF SWEDEN (RISE) INITIATES SUBSCRIPTION TO BIOINFOGATE OFF-X
Bioinfogate announced today the signing of a licensing agreement with RISE to access Bioinfogate’s translational safety intelligence portal, OFF-X.
RISE selected OFF-X to support the work of researchers in drug R&D to perform target safety assessment for early projects. The agreement involves the use of OFF-X safety intelligence portal to more quickly and precisely identify potential adverse events resulting from treatment with new and existing drugs.
By delivering critical integrated preclinical toxicity and clinical adverse event intelligence coupled to advanced analytics, Bioinfogate OFF-X™ allows safety liabilities to be monitored and anticipated across all phases of drug R&D. Updated daily with expertly curated safety alerts, as of June 2019, the portal covers a range of 7,700 targets and more than 10,000 drugs & biologics, and is populated with more than 340,000 alerts associated to 5,000 adverse effects. OFF-X covers targets and drugs in all stages of drug R&D development from emerging and first-in-class targets to drugs that have reached the marketplace. OFF-X aims to promptly identify toxicology & safety signals and de-risk R&D programs.
“We are very pleased that RISE is joining the growing number of leading research institutions using OFF-X as an essential tool for their drug safety and toxicology related activities” commented Josep Prous, Jr., Executive Director, Bioinfogate.
Bioinfogate is a forward thinking, private company working to solve unmet medical needs. Bioinfogate helps companies, academic institutions, and government and regulatory agencies working in scientific research and drug R&D. Our innovative knowledge management tools and analytics software solutions support the discovery and development of better and safer drugs. We are committed to building industry-leading solutions and identifying and investing in emerging projects that align with our core business in life sciences and data analytics.
Our passion and capabilities stem from more than 60 years’ experience creating and managing biomedical knowledge, first at Prous Science (acquired by Thomson Reuters in 2007), and then at the Prous Institute for Biomedical Research. Bioinfogate is the next generation firm within the Prous family of companies, embracing a long tradition and expertise in scientific knowledge management.
For more information please contact us at firstname.lastname@example.org.
FDA AND BIOINFOGATE AGREE TO EXTEND FOR 2 ADDITIONAL YEARS THE MATERIAL TRANSFER AGREEMENT (MTA) TO PROVIDE AGENCY-WIDE ACCESS TO THE OFF-X TRANSLATIONAL SAFETY INTELLIGENCE PORTAL
The agreement aims to evaluate new approaches to enhance safety assessments of human pharmaceuticals and their associated molecular targets, supporting the FDA’s mission of protecting public health.
May 12 ,2021
EXTERNAL VALIDATION OF BIOINFOGATE’S OFF-X FAERS CURATION PROCESS & STATISTICAL SIGNAL EXTRACTION TO BE SUPPORTED BY INTAGE HEALTHCARE’S CZEEKV PRO
Bioinfogate has established an agreement with INTAGE Healthcare to perform an external validation of their methodologies to curate information from FAERS and extract safety signals using well-established statistical methods with the CzeekV Pro database system.
Mar 22 ,2021
BIOINFOGATE’S OFF-X REACHES ONE MILLION SAFETY ALERTS
OFF-X has become the largest translational safety and toxicity intelligence portal for drugs and targets of pharmacological interest.
Jan 18 ,2021
NEW COLLABORATION BETWEEN BIOINFOGATE AND INTAGE HEALTHCARE TO DELIVER JAPANESE PHARMACOVIGILANCE INSIGHTS IN OFF-X
Bioinfogate will integrate JADER case reports and pharmacovigilance signals into OFF-X to complement its unique translational view of safety intelligence.
Oct 15 ,2020